Jafron Biomedical Co

Jafron Biomedical Co EBIT Growth

The Year-over-Year EBIT Growth of Jafron Biomedical Co (300529.SZ) as of Nov 13, 2026 is -29.26 %. In the previous year, Year-over-Year EBIT Growth was 92.23 % — a change of -131.72% (lower).

EBIT Growth

-29.26 %

YoY

-131.72%

Last updated:

Year-over-Year EBIT Growth of Jafron Biomedical Co is 2025 -29.26 % . Year-over-Year EBIT Growth of Jafron Biomedical Co was 2024 92.23 % . It decreases by -131.72% lower compared to the previous year.

The Jafron Biomedical Co EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2018
43.59 CNY
Jan 1, 2019
42.83 CNY
Jan 1, 2020
54.98 CNY
Jan 1, 2021
34.48 CNY
Jan 1, 2022
-27.40 CNY
Jan 1, 2023
-47.17 CNY
Jan 1, 2024
92.23 CNY
Jan 1, 2025
-29.26 CNY
The Jafron Biomedical Co EBIT Growth history
YEAREBIT GrowthYoY
-29.26 %-131.72%
92.23 %-295.50%
-47.17 %+72.19%
-27.40 %-179.45%
34.48 %-37.28%
54.98 %+28.35%
42.83 %-1.74%
43.59 %+2.40%
42.57 %+15,690.80%
0.27 %-99.19%
33.32 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Jafron Biomedical Co Stock analysis

What does Jafron Biomedical Co do? Jafron Biomedical Co., Ltd. generates revenue through the research, development, production, and sale of hemoperfusion products and medical equipment. The company offers a range of items including disposable hemoperfusion devices, hemoperfusion machines, disposable bilirubin adsorbers, the DX-10 blood purification machine, suture needles, and resins bandage. These products are utilized for treating conditions such as uremia, poisoning, severe liver diseases, autoimmune diseases, and multisystem organ failure. The primary customers for these medical solutions are hospitals across China, where the company’s products are applied in more than 3000 hospitals within 31 provinces. As a China-based company, Jafron Biomedical Co., Ltd. focuses on the design, manufacture, and distribution of biological materials and medical equipment to support healthcare providers in these regions. The company operates from its headquarters in Zhuhai, Guangdong, and supports its operations with a workforce of 3,003 full-time employees. By engaging in the full lifecycle of its products from research to sale, the firm serves the medical sector with specialized equipment for blood purification and related therapeutic needs. Jafron Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jafron Biomedical Co stock

Year-over-Year EBIT Growth of Jafron Biomedical Co is -29.26 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth Jafron Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's Jafron Biomedical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Growth — Jafron Biomedical Co

Revenue GrowthRevenue CAGR 3YRevenue CAGR 5YRevenue CAGR 10YEarnings GrowthEPS GrowthEBIT GrowthEBIT CAGR 3YEBIT CAGR 5YEBIT CAGR 10YDividend GrowthFCF GrowthBook Value GrowthEarnings CAGR 3YEarnings CAGR 5YEarnings CAGR 10YEPS CAGR 3YEPS CAGR 5YEBITDA Growth YoYEBITDA CAGR 3YEBITDA CAGR 5YGross Profit GrowthOCF Growth YoYEmployee GrowthDividend CAGR 3YDividend CAGR 5YDividend CAGR 10YAsset GrowthEquity GrowthDebt GrowthCapEx GrowthFCF CAGR 3YFCF CAGR 5YMarket Cap GrowthShare Count Growth

All Key Metrics — Jafron Biomedical Co